Skip to main content
. 2021 Feb 13;10(3):220–229. doi: 10.1002/psp4.12592

Figure 3.

Figure 3

Model predictions on the effect of binding affinity on NKG2A receptor occupancy (RO) in the tumor over various dosing periods. (a) Semi‐log plot shows the RO in the tumor at day 14 at a range of doses and binding affinities. In our model, the affinities of the KSQ monoclonal antibody (mAb) and monalizumab are 25 pM and 2.5 nM, respectively. (b) Contour plots illustrate the NKG2A tumor coverage as a function of a single dose and binding affinity using q3w and (c) q4w dosing regimens